drugset / Trial / NCT05201781

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781

Phase 4 Recruiting 295 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Timeline

Start
2022-03-09
Primary completion
2037-07-29
Completion
2042-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ciltacabtagene autoleucel Cell therapy

Indications